Prevalence of Signs and Symptoms of Pseudotumor Cerebri Syndrome Before and After Transsphenoidal Surgery for Cushing’s Disease – A Prospective Consecutive Case Series

Abstract

Introduction Pseudotumor cerebri syndrome (PTCS) has anecdotally been described after successful treatment of Cushing’s disease (CD), but the prevalence following transsphenoidal surgery has not been determined so far in a prospective study.

Patients and Methods 41 consecutive adult CD patients were prospectively screened for signs and symptoms of PTCS, headache-related impairment, and ophthalmological features associated with intracranial pressure elevation before surgery and at follow-up (mean 4 months).

Results Biochemical remission was achieved in 36 of 41 (87.8%) patients after surgery. The most frequent preoperative complaints were visual acuity impairment (19 cases; 46.3%), headache (13 cases; 31.7%), and ear noise (9 cases; 22.0%). A significant reduction of visual disturbances was seen at follow-up. Overall, CD patients presented with fairly low headache-related emotional and functional restrictions before and after surgery. One of 34 (2.9%) patients with sufficient ophthalmological follow-up showed new-onset papilledema combined with temporary worsening of visual acuity and scotoma.

Conclusion Our results suggest a very low frequency of signs and symptoms of PTCS after surgical treatment for CD in adults. This estimate is in line with previous outcomes from retrospective pediatric CD series. Further large-scale studies are needed to determine the actual prevalence of this condition following biochemical remission of CD.

Key words

Pituitary adenoma<Cancer - Glucocorticoids<Hormones - Hypopituitarism<Insufficiencies

• References

• 1 Martin NA, Linfoot J, Wilson CB. Development of pseudotumor cerebri after the removal of an adrenocorticotropic hormone-secreting pituitary adenoma. Neurosurgery 1981; 8: 699-702
• 2 Weissman MN, Page LK, Bejar RL. Cushing’s disease in childhood: Benign intracranial hypertension after trans-sphenoidal adenomectomy. Neurosurgery 1983; 13: 195-198
• 3 Marechaud R, Boissonnot M, Holderer-Fieuzal S. et al. Idiopathic intracranial hypertension during treatment of Cushing’s disease with mitotane. Presse Med 1987; 16: 2131
• 4 Parfitt VJ, Dearlove JC, Savage D. et al. Benign intracranial hypertension after pituitary surgery for Cushing’s disease. Postgraduate Medical Journal 1994; 70: 115-117
• 5 Kiehna EN, Keil M, Lodish M. et al. Pseudotumor cerebri after surgical remission of cushing’s disease. The Journal of Clinical Endocrinology & Metabolism 2010; 95: 1528-1532
• 6 Costenaro F, Rodrigues TC, Ferreira NP. et al. Pseudotumor cerebri during Cushing’s disease treatment with ketoconazole. Arq Bras Endocrinol Metabol 2011; 55: 284-287
• 7 Wagner J, Fleseriu CM, Ibrahim A. et al. Idiopathic intracranial hypertension after surgical treatment of cushing disease: Case report and review of management strategies. World Neurosurgery 2016; 96: 611.e15-611.e18
• 8 Newman PK, Snow M, Hudgson P. Benign intracranial hypertension and Cushing’s disease. Br Med J 1980; 281: 113
• 9 Salpietro V, Polizzi A, Bertè LF. et al. Idiopathic intracranial hypertension: a unifying neuroendocrine hypothesis through the adrenal-brain axis. Neuro Endocrinol Lett 2012; 33: 569-573
• 10 World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194
• 11 Agha RA, Borrelli MR, Farwana R. et al. The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. International Journal of Surgery 2018; 60: 279-282
• 12 Kelley K. Good practice in the conduct and reporting of survey research. International Journal for Quality in Health Care 2003; 15: 261-266
• 13 Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013; 81: 1159-1165
• 14 Zada G. Diagnosis and Multimodality Management of Cushing’s Disease: A Practical Review. International Journal of Endocrinology 2013; 2013: 1-7
• 15 Nieman LK, Biller BMK, Findling JW. et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. The. Journal of Clinical Endocrinology & Metabolism 2008; 93: 1526-1540
• 16 Lüdecke DK, Flitsch J, Knappe UJ. et al. Cushing’s disease: A surgical view. J Neurooncol 2001; 54: 151-166
• 17 Teramoto A, Yoshida Y, Sanno N. et al. Cavernous sinus sampling in patients with adrenocorticotrophic hormone—dependent Cushing’s syndrome with emphasis on inter- and intracavernous adrenocorticotrophic hormone gradients. Journal of Neurosurgery 1998; 89: 762-768
• 18 Flitsch J, Lüdecke D, Knappe U. et al. Cavernous sinus sampling in selected cases of cushing’s disease. Exp Clin Endocrinol Diabetes 2002; 110: 329-335
• 19 Mollan SP, Davies B, Silver NC. et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 2018; 89: 1088-1100
• 20 Wüllner DU. Idiopathische intrakranielle Hypertension (IIH), S1-Leitlinie Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien
• 21 Jacobson GP, Ramadan NM, Aggarwal SK. et al. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology 1994; 44: 837-837
• 22 Bauer B, Evers S, Gralow I. et al. Psychosoziale Beeinträchtigung durch chronische Kopfschmerzen. Der Nervenarzt 1999; 70: 522-529
• 23 Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-197
• 24 Milian M, Teufel P, Honegger J. et al. The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part I: Construction and psychometric properties. Clin Endocrinol (Oxf). 2012; 76: 851-860
• 25 Milian M, Teufel P, Honegger J. et al. The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part II: Normative data from 1784 healthy people. Clin Endocrinol (Oxf) 2012; 76: 861-867
• 26 Wall M, Kupersmith MJ, Kieburtz KD. et al. The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline. JAMA Neurol 2014; 71: 693
• 27 Esposito F, Dusick JR, Cohan P. et al. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 2006; 91: 7-13
• 28 Johnston I, Gilday DL, Hendrick EB. Experimental effects of steroids and steroid withdrawal on cerebrospinal fluid absorption. Journal of Neurosurgery 1975; 42: 690-695
• 29 Weiss MH, Nulsen FE. The effect of glucocorticoids on CSF flow in dogs. J Neurosurg 1970; 32: 452-458
• 30 Sato O, Hara M, Asai T. et al. The effect of dexamethasone phosphate on the production rate of cerebrospinal fluid in the spinal subarachnoid space of dogs. Journal of Neurosurgery 1973; 39: 480-484
• 31 Zada G, Tirosh A, Kaiser UB. et al. Cushing’s disease and idiopathic intracranial hypertension: Case report and review of underlying pathophysiological mechanisms. The Journal of Clinical Endocrinology & Metabolism 2010; 95: 4850-4854
• 32 Oshio K, Watanabe H, Song Y. et al. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1. FASEB J 2005; 19: 76-78
• 33 Moon Y, Hong SJ, Shin D. et al. Increased aquaporin-1 expression in choroid plexus epithelium after systemic hyponatremia. Neurosci Lett 2006; 395: 1-6
• 34 Cote DJ, Alzarea A, Acosta MA. et al. Predictors and rates of delayed symptomatic hyponatremia after transsphenoidal surgery: a systemastic review. World Neurosurgery 2016; 88: 1-6
• 35 Patil CG, Lad SP, Katznelson L. et al. Brain atrophy and cognitive deficits in Cushing’s disease. FOC 2007; 23: 1-4
• 36 Starkman MN, Giordani B, Gebarski SS. et al. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry 1999; 46: 1595-1602
• 37 Jiang H, Ren J, He N-Y. et al. Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing’s disease. Clin Endocrinol 2017; 87: 367-374
• 38 Jiang H, Liu C, Pan S-J. et al. Reversible and the irreversible structural alterations on brain after resolution of hypercortisolism in Cushing’s disease. Steroids 2019; 151: 108457
• 39 Dimopoulou C, Athanasoulia AP, Hanisch E. et al. Clinical characteristics of pain in patients with pituitary adenomas. European Journal of Endocrinology 2014; 171: 581-591
• 40 Buliman A, Tataranu LG, Paun DL. et al. Cushing’s disease: A multidisciplinary overview of the clinical features, diagnosis, and treatment. J Med Life 2016; 9: 12-18
• 41 Bouzas EA, Scott MH, Mastorakos G. et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993; 111: 1229-1233
• 42 Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010; 24: 1743-1756
• 43 Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994; 41: 359-364
• 44 Fomekong E, Maiter D, Grandin C. et al. Outcome of transsphenoidal surgery for Cushing’s disease: A high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg 2009; 111: 442-449
• 45 Broersen LHA, Biermasz NR, van Furth WR. et al. Endoscopic vs. microscopic transsphenoidal surgery for Cushing’s disease: A systematic review and meta-analysis. Pituitary 2018; 21: 524-534
• 46 Broersen LHA, Andela CD, Dekkers OM, et al. Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushing’s syndrome. The Journal of Clinical Endocrinology & Metabolism 2019; jc.2019-01054
• 47 Fisayo A, Bruce BB, Newman NJ. et al. Overdiagnosis of idiopathic intracranial hypertension. Neurology 2016; 86: 341-350